EGFR and non-small cell lung carcinoma: Therefore, we hypothesize that the abnormal or unscheduled activation of the development of the important PKC signaling pathway may be associated with NSCLC progression and the combination of the EGFR inhibitor erlotinib with the PKC inhibitor chelerythrine may be a potential therapeutic strategy in NSCLC.